← Russell 3000 cross-section

RXRX RECURSION PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$1.9bn
Revenue TTM
$55m
Net income TTM
$-519m
Free cash flow
$-352m
Composite score
32.1
Sector rank
#1682

Valuation

P / E
EV / EBITDA
EV / sales
23.9
FCF yield
-18.96%
Earnings yield vs 10-yr
-32.66pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-945.9%
EBITDA margin
-848.9%
ROE
-56.7%
ROIC
-147.3%
Revenue growth
-15.1%

Insider activity, last 90 days

Net open-market
$-0.62m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The collaboration includes up to 40 potential small molecule discovery programs, each carrying the potential for more than $300 million in development, commercialization, and net sales milestones as well as tiered royalties up to high single digits per small molecule program for Recursion. In February 2025, the Company terminated the Sales Agreement with Jefferies LLC and entered into a Sales Agreement with Citigroup Capital Markets Inc., to provide for the offering, issuance and sale of up to an aggregate amount of $500.0 million of its Class A common stock. Pursuant to its terms, the Sales Agreement was completed and no amount remained available for future sales. …RECURSION PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →